{
  "id": "gap_index_ipf_mortality",
  "title": "GAP Index for Idiopathic Pulmonary Fibrosis (IPF) Mortality",
  "description": "Provides 1, 2, and 3-year mortality estimates for IPF patients. The GAP Index uses Gender, Age, and Physiology (FVC and DLCO) to predict mortality risk and guide clinical management decisions.",
  "category": "pulmonology",
  "version": "2012",
  "parameters": [
    {
      "name": "gender",
      "type": "string",
      "required": true,
      "description": "Patient's gender (males have higher mortality risk in IPF)",
      "options": ["male", "female"],
      "validation": {
        "enum": ["male", "female"]
      }
    },
    {
      "name": "age",
      "type": "integer",
      "required": true,
      "description": "Patient's age in years",
      "validation": {
        "min": 18,
        "max": 100
      },
      "unit": "years"
    },
    {
      "name": "fvc_percent_predicted",
      "type": "float",
      "required": true,
      "description": "Forced Vital Capacity (FVC) as percentage of predicted normal value",
      "validation": {
        "min": 10,
        "max": 150
      },
      "unit": "percent"
    },
    {
      "name": "dlco_percent_predicted",
      "type": "float",
      "required": false,
      "description": "Diffusing capacity for carbon monoxide (DLCO) as percentage of predicted normal value. Use null if cannot perform test",
      "validation": {
        "min": 5,
        "max": 150
      },
      "unit": "percent"
    }
  ],
  "result": {
    "name": "gap_score",
    "type": "integer",
    "unit": "points",
    "description": "GAP score calculated from gender, age, and physiology parameters (0-8 points)"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 0,
        "max": 3,
        "stage": "GAP Stage I",
        "description": "Low mortality risk",
        "interpretation": "Low mortality risk. Close monitoring every 6 months. Aggressive symptom management and comorbidity treatment. May not require immediate lung transplant listing."
      },
      {
        "min": 4,
        "max": 5,
        "stage": "GAP Stage II",
        "description": "Intermediate mortality risk",
        "interpretation": "Intermediate mortality risk. Close monitoring every 3-6 months. Consider lung transplant evaluation. Optimize medical management and consider antifibrotic therapy."
      },
      {
        "min": 6,
        "max": 8,
        "stage": "GAP Stage III",
        "description": "High mortality risk",
        "interpretation": "High mortality risk. Frequent monitoring every 3 months or less. Urgent lung transplant evaluation recommended. Palliative care consultation may be appropriate."
      }
    ]
  },
  "references": [
    "Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-91. doi: 10.7326/0003-4819-156-10-201205150-00004.",
    "Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723-8. doi: 10.1378/chest.13-1474.",
    "Paterniti MO, Bi Y, RekiÄ‡ D, et al. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC."
  ],
  "formula": "GAP Score = Gender points + Age points + FVC points + DLCO points (0-8 total)",
  "notes": [
    "Validated in 558 IPF patients from three academic centers in US and Italy",
    "Can be used both at presentation and during follow-up throughout disease course",
    "Stage I (0-3 points): Monitor every 6 months, may not need immediate transplant listing",
    "Stage II (4-5 points): Monitor every 3-6 months, consider transplant evaluation",
    "Stage III (6-8 points): Monitor every 3 months, urgent transplant evaluation",
    "Higher GAP scores associated with significantly poorer prognosis (p<0.001)",
    "DLCO cannot perform = 3 points (most severe category)",
    "Antifibrotic therapy may be considered for all stages but especially Stage II-III",
    "Should be used in conjunction with clinical judgment and other prognostic factors",
    "Validated for use in idiopathic pulmonary fibrosis specifically"
  ]
}